Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study

被引：0

作者：

Carpentier, Antoine F.

Verlut, Clotilde

Ghiringhelli, Francois

Bronnimann, Charlotte

Ursu, Renata

Fumet, Jean David

Gherga, Elisabeta

Lefort, Felix

Belin, Catherine

Vernerey, Dewi

Hervieu, Alice

Laheurte, Caroline

Meurisse, Aurelia

Jacquin, Marion

Malfroy, Marine

Fagnoni-Legat, Christine

Lehmann-Che, Jacqueline

Boullerot, Laura

Cuzzubbo, Stefania

Adotevi, Olivier

机构：

[1] Hop St Louis, Paris, France

[2] Univ Hosp Besancon, Dept Neurol, F-25000 Besancon, France

[3] Ctr GF LECLERC, Early Clin Unit CLIP2 INCA, Dijon, France

[4] Hop St Andre, Bordeaux, France

[5] St Louis Hosp, AP HP, Dept Neurol, Paris, France

[6] UNICANCER, Georges Francois Leclerc Canc Ctr, Dijon, France

[7] Hop Nord Franche Comte, Dept Radiotherapy, Montbeliard, France

[8] Univ Bordeaux, Dept Med Oncol, Hop St Andre, CHU Bordeaux, Bordeaux, France

[9] Paris Cite Univ, Dept Neurol, St Louis Hosp, AP HP, Paris, France

[10] UMQVC, Besancon, France

[11] Univ Hosp Besancon, Besancon, France

[12] Ctr Georges Francois Leclerc, Dijon, France

[13] Univ Franche Comte, INSERM, EFS UFC, UMR1098,RIGHT, Besancon, France

[14] CHU Jean Minjoz Besancon, Besancon, France

[15] Univ Hosp Besancon, INSERM CIC 1431, Clin Invest Ctr, Besancon, France

[16] Univ Bourgogne Franche Comte, INSERM, EFS BFC, RIGHT,UMR1098, Besancon, France

[17] Univ Hosp Besancon, Dept Pharm, Besancon, France

[18] St Louis Hosp Paris, Paris, France

[19] Univ Hosp Besancon, Dept Med Oncol, Besancon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2005

引用

页数：1

共 50 条

[41] A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Initial report of the CORE study
Nabors, L.
Fink, K.
Mikkelsen, T.
Grujicic, D.
Tarnawski, R.
Nam, D.
Perry, J.
Markivskyy, A.
Picard, M.
Reardon, D.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S17 - S18
[42] Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated
O'Brien, Barbara J.
De Groot, John
Kamiya-Matsuoka, Carlos
Weathers, Shiao-Pei
Bacha, Jeffrey A.
Brown, Dennis M.
Steino, Anne
Langlands, John
Schwartz, Richard
Kanekal, Sarath
Lopez, Lorena
Penas-Prado, Marta
CANCER RESEARCH, 2018, 78 (13)
[43] FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE
Tabatabai, Ghazaleh
Freres, Pierre
Glas, Martin
Hau, Peter
von Baumgarten, Louisa
van den Bent, Martin
Burger, Michael C.
Seidel, Clemens
Herrlinger, Ulrich
Mildenberger, Iris
Neyns, Bart
Schafer, Henning
Wick, Antje
Falk, Martin
de Chama, Laura Leticia Freitas
Kelemen, Peter
Schwenke, Frauke
Koch, Sven D.
Roche, Paula Romer
Gnad-Vogt, Ulrike
NEURO-ONCOLOGY, 2024, 26
[44] Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick, Wolfgang
Gorlia, Thierry
Bady, Pierre
Platten, Michael
van den Bent, Martin J.
Taphoorn, Martin J. B.
Steuve, Jonathan
Brandes, Alba A.
Hamou, Marie-France
Wick, Antje
Kosch, Markus
Weller, Michael
Stupp, Roger
Roth, Patrick
Golfinopoulos, Vassilis
Frenel, Jean-Sebastien
Campone, Mario
Ricard, Damien
Marosi, Christine
Villa, Salvador
Weyerbrock, Astrid
Hopkins, Kirsten
Homicsko, Krisztian
Lhermitte, Benoit
Pesce, Gianfranco
Hegi, Monika E.
CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4797 - 4806
[45] MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Gerstner, E. R.
Yip, S.
Wang, D. L.
Louis, D. N.
Iafrate, A. J.
Batchelor, T. T.
NEUROLOGY, 2009, 73 (18) : 1509 - 1510
[46] PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: CASE STUDY REPORTS
Guo, C.
Yang, Q.
Li, J.
Wu, S.
Cao, X.
Deng, M.
Du, X.
Bacha, J.
Kanekal, S.
Kwan, C.
Johnson, G.
Schwartz, R.
Langlands, J.
Brown, D.
Chen, Z.
NEURO-ONCOLOGY, 2023, 25 : 83 - 83
[47] A PHASE I STUDY OF EGFRVIII-DIRECTED CAR T CELLS COMBINED WITH PD-1 INHIBITION IN PATIENTS WITH NEWLY, DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA: TRIAL IN PROGRESS
Bagley, Stephen
Desai, Arati
Binder, Zev
Nasrallah, MacLean
Hwang, Wei-Ting
Maloney-Wilensky, Eileen
Prior, Timothy
Brem, Steven
O'Rourke, Donald
NEURO-ONCOLOGY, 2019, 21 : 221 - 221
[48] Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549)
Goplen, Dorota
Rahman, Mohummad Aminur
Brekke, Jorunn
Arnesen, Victoria Smith
Simonsen, Anne
Waha, Andreas
Marienhagen, Kirsten
Oltedal, Leif
Haasz, Judit
Miletic, Hrvoje
Solheim, Tora Skeidsvoll
Brandal, Petter
Lie, Stein Atle
Chekenya, Martha
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Chen, Zhong-ping
Guo, Cheng-Cheng
Yang, Qun-ying
Wu, Shao-xiong
Li, Jia-Wei
Bacha, Jeffrey
Johnson, Greg
Langlands, John
Schwartz, Richard
Kwan, Claire
Kanekal, Sarath
Steino, Anne
Lopez, Lorena
Brown, Dennis
NEURO-ONCOLOGY, 2020, 22 : 60 - 60
[50] Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma -: A phase II study
Weller, M
Streffer, J
Wick, W
Kortmann, RD
Heiss, E
Küker, W
Meyermann, R
Dichgans, J
Bamberg, M
CANCER, 2001, 91 (02) : 423 - 427

← 1 2 3 4 5 →